CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 30 enrolled
Drug / intervention
intravenous immunoglobulindrug
Likely dose
intravenous immunoglobulin 200 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05134792
NCT05134792Phase 3Completed
CompareCT.gov

Effect of Pre-emptive Intravenous Immunoglobulin Administration on the Incidence of Septic Episodes in Pediatric Burn Patients: A Randomized Controlled Study

Cairo University·interventional·Posted Nov 26, 2021·Updated Nov 15, 2022

In Brief

A Phase 3 clinical trial evaluating intravenous immunoglobulin for Burn Shock. Completed, enrolled 30 participants across 1 site.

Detailed Summary

Effect of pre-emptive intravenous immunoglobulin administration on the incidence of septic episodes in pediatric burn patients: A randomized controlled study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBurn Shock
CountriesEgypt
Collaborators--

Timeline

Phase 3CompletedFinished
20222023202420252026
First PostedNov 26, 2021
Enrollment StartOct 10, 2021
Primary CompletionJul 16, 2022
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 4.6 years ago

Interventions

intravenous immunoglobulindrug

All pediatric burn patients allocated in group intra venous immunoglobulin admitted will receive 200 mg/kg IVIG once after their initial resuscitation before 48 hours passes of burn incident.